A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

Bristol-Myers Squibb0 个研究点目标入组 665 人开始时间: 待定最近更新: 2024年7月24日

试验速览

暂无简介。

•Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis
•Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
•Eastern Cooperative Oncology Group Performance Status of 0 or 1
•Radiographically documented progressive disease on or after the most recent therapy
•Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated
•Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant

•Women who are pregnant or breastfeeding
•Primary central nervous system (CNS) malignancy
•Untreated CNS metastases
•Leptomeningeal metastases
•Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment
•Active, known, or suspected autoimmune disease
•Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment
•Prior organ or tissue allograft
•Uncontrolled or significant cardiovascular disease
•Major surgery within 4 weeks of study drug administration
•History of or with active interstitial lung disease or pulmonary fibrosis

adverse event, serious adverse event, dose-limiting toxicity, etc.

未报告次要终点

发起方

Bristol-Myers Squibb